2024 #Retina Pipeline

🎥 Dr. Deepak Sambhara,breaks down the latest advancements in retinal therapy. In this video, he highlights the game-changers in VEGF inhibition, including the exciting phase 3 trials of Opthea's OPT-302, a VEGF-C/D inhibitor. But that's not all—tyrosine kinase inhibitors (TKIs) are pushing boundaries with their unique intracellular approach! Companies like Ocular Therapeutix, Eyepoint Pharmaceuticals, and ClearSight Biomedical are pioneering this new frontier. 🔍 Key Highlights: VEGF-A: The cornerstone of angiogenesis, targeted by all current anti-VEGF therapies. OPT-302: A promising candidate inhibiting VEGF-C/D paired with ranibizumab or aflibercept. Tyrosine Kinase Inhibitors (TKIs): A novel approach with companies like Ocular Therapeutix and Eyepoint Pharmaceuticals leading the charge with cutting-edge implants. 🧠 Why It Matters: These innovations could redefine retinal treatment, offering new hope for patients with challenging conditions. Whether it's through extracellular or intracellular mechanisms, the future of #retina care is evolving rapidly. #Retina #Ophthalmology #Innovation #VEGF #TKI #RetinaSpecialist #EyeCare Financial Disclosures: Dr. Sambhara has financial disclosures with Apellis, Astellas Pharma, Eclipse Life Sciences, Genentech, Heidelberg Engineering, Ocular Therapeutix and Regeneron.